Novo Nordisk is preparing to launch its Wegovy weight-loss pill outside the U.S. later this year, targeting major international markets like the UK, Germany, and Denmark. The company sees a significant opportunity to expand globally, leveraging telehealth to increase patient access. Despite strong U.S. sales, Novo expects some sales decline in 2026 due to pricing pressures and generic competition. The global rollout marks a new phase in competition with Eli Lilly, which also recently launched a rival weight-loss pill, Foundayo. Novo expects strong uptake internationally but anticipates a different sales curve compared to the U.S., with many patients paying out of pocket in socialized healthcare systems.
Novo Nordisk's stock surged 25% in the past month, recovering from multi-year lows due to the launch of oral versions of its Ozempic and Wegovy weight loss drugs, FDA approvals, and telehealth partnerships. The company also slightly raised its sales ...
Novo Nordisk presented new phase 3 trial data showing that adults taking the Wegovy pill (oral semaglutide 25 mg) achieved meaningful weight loss, with early responders losing up to 21.6% body weight by week 64. Even those not classified as early res...
